Is BioVie Inc. (BIVI) a Buy, Sell, or Hold?
BioVie Inc.
NASDAQ:BIVI
$1.58 USD
-$0.06 (-3.66%)
- Volume
- 270.19K
- Average Volume
- 132.57K
- Market Capitalization
- $11.92M
- P/E Ratio
- -1.07
- Dividend Yield
- 0.00%
- Price Target
- $
- Year High
- $9.09
- Year Low
- $1.06
- Day High
- —
- Day Low
- —
- Payout Ratio
- $0.00
- Current Ratio
- $9.97
Industry, Sector & symbol
| Stock Exchange | NASDAQ |
| CEO | Cuong Viet Do |
| Industry | Biotechnology |
| Sector | Healthcare |
| Current Symbol | BIVI |
| CUSIP | 09074F504 |
| CIK | 0001580149 |
| Web | https://bioviepharma.com |
| Phone | 775 888 3162 |
| Currency | USD |
| Employees | 13 |
| Country | US |
Liquidity
| Debt-to-Equity Ratio | 0.02 |
| Payout Ratio | 0.00 |
| Current Ratio | 9.97 |
| Quick Ratio | 9.97 |
| Cash Ratio | 7.73 |
Sales & Book Value
| Annual Sales | $- |
| Price / Sales | 0.00 |
| Cash Flow | -2.72 |
| Price / Cash Flow | -0.58 |
| Price / Book | 0.76 |
Price Target and Rating
| Average Stock Price Forecast | $ |
| High Stock Price Forecast | $ |
| Low Stock Price Forecast | $ |
| Forecast Upside/Downside | % |
| Consensus Rating | Neutral |
| Rating Score(0-5) | 3 |
| Research Coverage | 5 Analysts |
Profitability
| EPS (Most Recent Fiscal Year) | $-12.12 |
| Trailing P/E Ratio | -1.07 |
| PEG Ratio | 0.00 |
| P/E Growth | 0.00 |
| Net Income | $-17.54M |
| Net Margin | 0.00% |
| Pretax Margin | 0.00% |
| Return on Equity | -101.09% |
| Return on Assets | -113.71% |
Financials Score
| AltmanZ Score | -28.24 |
| Piotroski Score | 1.00 |
| Working Capital | 15.19M |
| Total Assets | 17.51M |
| Ebit | -19.94M |
| Market Cap | 12.52M |
| Total Liabilities | 1.91M |
Poll Results
About BioVie Inc. (NASDAQ:BIVI) Stock
BioVie Inc. is a clinical-stage biotechnology firm primarily dedicated to the discovery, development, and commercialization of innovative drug treatments across the United States. The company's developmental portfolio includes BIV201, a therapeutic agent that has successfully completed its Phase IIa clinical trial for addressing ascites resulting from chronic liver cirrhosis. Additionally, BioVie is advancing NE3107, which is currently undergoing a Phase III clinical trial for the management of mild to moderate Alzheimer's disease, and is also in a Phase I clinical trial for the treatment of Parkinson's disease. Further preclinical investigations are underway for NE3107, exploring its potential applications in treating multiple myeloma and prostate cancer. Established in 2013, the company ... adopted its current name, BioVie Inc., in July 2016, having previously operated as NanoAntibiotics, Inc. Its corporate headquarters are situated in Carson City, Nevada.
Did BioVie Inc. Insiders Breach their Fiduciary Duties to Shareholders?
2026-06-05 15:31:00
Shareholders are encouraged to contact the firm to discuss their rights and options at no cost or obligation. We would handle any matter on a contingent fee basis, whereby you would not be responsible for out-of-pocket payment of our legal fees or expenses.
2026-06-02 20:52:07
BioVie Inc. (BIVI) Discusses Clinical Updates on Bezisterim and BIV201 for Parkinson's, Alzheimer's, and Ascites Transcript
BioVie: Long COVID trial fully enrolled – ICYMI
2026-05-29 16:31:33
BioVie Inc (NASDAQ:BIVI, NASDAQ:BIVIW) earlier this week announced that its Phase 2 long COVID trial evaluating bezisterim has achieved full enrollment, marking an important milestone for the biotechnology company as it advances a potential treatment for patients suffering persistent post-COVID symptoms. Speaking with Proactive, CEO Cuong Do said the study enrolled more than 200 long COVID patients with support from major medical institutions including Yale, Mount Sinai, Mayo Clinic and Stanford.
BioVie: Long COVID trial fully enrolled – ICYMI
2026-05-29 12:30:00
BioVie Inc (NASDAQ:BIVI, NASDAQ:BIVIW) earlier this week announced that its Phase 2 long COVID trial evaluating bezisterim has achieved full enrollment,...
Join BioVie's Exclusive Live Investor Webinar and Q and A Session on June 2
2026-05-27 08:00:00
CARSON CITY, Nev., May 27, 2026 (GLOBE NEWSWIRE) -- BioVie Inc. (NASDAQ: BIVI) (“BioVie” or the “Company”), a clinical-stage company developing innovative drug therapies for neurological and neurodegenerative diseases, is pleased to invite investors to a webinar on June 2, 2026, at 4:15 p.m.
BioVie to highlight neuro and liver disease programs in June 2 investor webinar
2026-05-27 06:09:00
BioVie Inc (NASDAQ:BIVI, NASDAQ:BIVIW) will host an investor webinar on June 2 at 4:15 p.m. ET featuring CEO Cuong Do. The discussion will focus on...
BioVie completes enrollment in Phase 2 Long COVID trial
2026-05-26 09:15:07
BioVie Inc (NASDAQ:BIVI, NASDAQ:BIVIW) said on Tuesday it has completed enrollment in its ADDRESS-LC Phase 2 clinical trial evaluating bezisterim for the treatment of neurological symptoms of Long COVID, with topline data expected later this summer. The trial, fully funded by a grant from the US Department of War, is testing whether bezisterim can address neurological and neuropsychiatric symptoms associated with Long COVID, including fatigue, cognitive dysfunction, post-exertional malaise and sleep disturbance.
2026-05-26 08:00:00
-Topline Data Release Targeted Late Summer 2026- CARSON CITY, Nev., May 26, 2026 (GLOBE NEWSWIRE) -- BioVie Inc. (NASDAQ: BIVI) (“BioVie” or the “Company”), a clinical-stage company developing innovative drug therapies for neurological and neurodegenerative diseases, today announced full enrollment of the Company's ADDRESS-LC Phase 2 trial evaluating its drug candidate bezisterim for the treatment of neurological symptoms of Long COVID.
Frequently Asked Questions
-
What is the current BioVie Inc. (BIVI) stock price?
-
BioVie Inc.(NASDAQ:BIVI) stock price is $1.58 in the last trading session. During the trading session, BIVI stock reached the peak price of $9.09 while $1.06 was the lowest point it dropped to. The percentage change in BIVI stock occurred in the recent session was --3.66% while the dollar amount for the price change in BIVI stock was -$-0.06.
-
BIVI's industry and sector of operation?
-
The NASDAQ listed BIVI is part of Biotechnology industry that operates in the broader Healthcare sector.
-
Who are the executives of BIVI?
-
Clarence N. Ahlem | Senior Vice President of Operations
Cuong Viet Do | President, Chief Executive Officer & Director
David Morse | Senior Vice President & Chief Regulatory Officer
Denise Smith | Senior Vice President of Manufacturing & Development
Joanne Wendy Kim | Chief Financial Officer, Treasurer & Corporate Secretary -
How many employees does BIVI have?
-
Number of BIVI employees currently stands at 13. BIVI operates from 680 West Nye Lane, Carson City, NV 89703, US.
-
Link for BIVI official website?
-
Official Website of BIVI is: https://bioviepharma.com
-
How do I contact BIVI?
-
BIVI could be contacted at phone #775 888 3162 and can also be accessed through its website. BIVI operates from 680 West Nye Lane, Carson City, NV 89703, US.
-
How many shares of BIVI are traded daily?
-
The average number of BIVI shares traded daily for last 3 months was 132.57K.
-
What is the market cap of BIVI currently?
-
The market value of BIVI currently stands at $11.92M with its latest stock price at $1.58